Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Martin Robert Leivers"'
Autor:
Subramanian Baskaran, Ramu Meesala, Bing Xia, Robert Hamatake, George Adjabeng, Wieslaw M. Kazmierski, Katja Remlinger, Martin Robert Leivers, Renae M. Crosby, Nagaraju Miriyala, Mallesh Beesu, Richard Martin Grimes, Jill Walker
Publikováno v:
Journal of Medicinal Chemistry. 63:4155-4170
Pan-genotype NS5A inhibitors underpin hugely successful hepatitis C virus (HCV) therapy. The discovery of GSK2818713 (13), a nonstructural protein 5A (NS5A) HCV inhibitor characterized by a significantly improved genotype coverage relative to first-g
Autor:
Frans van der Berg, Steve R. Hood, Dickens Theodore, Joanne Saunders, Shuguang Chen, Melanie Paff, Matt Davies, David Gardiner, Jennifer Cremer, Jan Losos, Sharon Baptiste-Brown, Martin Robert Leivers, Stuart Oliver, James M Ritter, Robert Hamatake, Robert Elston, Kelong Han
Publikováno v:
Clinical Pharmacology in Drug Development
GSK3389404 is a liver‐targeted antisense oligonucleotide that inhibits synthesis of hepatitis B surface antigen and all other hepatitis B virus proteins. This first‐in‐human, randomized, double‐blind, phase 1 study assessed the safety and pha
Autor:
George N. Dalekos, Spilios Manolakopoulos, Gabor Horvath, Robert Hamatake, Tivadar Banyai, Yanli Deng, Ioannis Goulis, Dickens Theodore, Martin Robert Leivers, George V. Papatheodoridis, Mark Deeg, Bernd Jilma, Soumi Lahiri, Fiona Campbell, Kelong Han, Michael Huang, Shuguang Chen
Publikováno v:
Journal of viral hepatitisREFERENCES. 27(7)
Single-visit cures for chronic hepatitis C are lacking. We conducted two clinical studies towards the goal of developing a regimen for single-visit cure. In a randomized, open-label, Phase 2 study (RG101-04), investigators enrolled 26 adult chronic h
Autor:
Andrew Maynard, Renae M. Crosby, Jill Walker, Maosheng Duan, Janos Botyanszki, Wieslaw M. Kazmierski, Scott Howard Dickerson, Robert Hamatake, Martin Robert Leivers, Christopher Don Roberts, Sam Baskaran, Matthew David Tallant, Rick Grimes
Publikováno v:
Journal of Medicinal Chemistry. 57:2058-2073
Rapid clinical progress of hepatitis C virus (HCV) replication inhibitors, including these selecting for resistance in the NS5A region (NS5A inhibitors), promises to revolutionize HCV treatment. Herein, we describe our explorations of diverse spiropy
Autor:
Amanda Mathis, Wenyan Mo, Susan Long, Stephanie Anna Chan, Jill Walker, Ryan Lauchli, Martin Robert Leivers, Elizabeth M. Turner, Tony Ton, Sebastian Liehr, J. Greg Falls, John F. Miller, Michael Youngman
Publikováno v:
Journal of Medicinal Chemistry. 57:1964-1975
By reducing the basicity of the core heterocycle in a series of HCV NS5B inhibitors, the hERG liability was reduced. The SAR was then systematically explored in order to increase solubility and enable dose escalation while retaining potency. During t
Autor:
Chris B. Moore, Anna L. Leivers, Octerloney B. McDonald, Amanda Mathis, Katrina L. Creech, Janos Botyanszki, Susan L. Strum, Martin Robert Leivers, J. Brad Shotwell, Matthew David Tallant, Sabrinia Rogers, Scott Howard Dickerson, Jeff Gobel
Publikováno v:
Journal of medicinal chemistry. 57(5)
Hepatitis C virus (HCV) assembles many host cellular proteins into unique membranous replication structures as a prerequisite for viral replication, and PI4KIIIα is an essential component of these replication organelles. RNA interference of PI4KIII